102 related articles for article (PubMed ID: 22929880)
1. Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential.
Namløs HM; Khelik K; Nakken S; Vodák D; Hovig E; Myklebost O; Boye K; Meza-Zepeda LA
Mol Oncol; 2023 Nov; 17(11):2432-2450. PubMed ID: 37622176
[TBL] [Abstract][Full Text] [Related]
2. A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.
de Nonneville A; Finetti P; Adelaide J; Lambaudie É; Viens P; Gonçalves A; Birnbaum D; Mamessier E; Bertucci F
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31412533
[TBL] [Abstract][Full Text] [Related]
3. Application of Multi-Omics Approach in Sarcomas: A Tool for Studying Mechanism, Biomarkers, and Therapeutic Targets.
Zou Z; Sun W; Xu Y; Liu W; Zhong J; Lin X; Chen Y
Front Oncol; 2022; 12():946022. PubMed ID: 35875106
[TBL] [Abstract][Full Text] [Related]
4. Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer.
Amiri Souri E; Chenoweth A; Cheung A; Karagiannis SN; Tsoka S
Br J Cancer; 2021 Aug; 125(5):748-758. PubMed ID: 34131308
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas.
Merry E; Thway K; Jones RL; Huang PH
NPJ Precis Oncol; 2021 Mar; 5(1):17. PubMed ID: 33674685
[TBL] [Abstract][Full Text] [Related]
6. Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience.
Orbach D; Mosseri V; Pissaloux D; Pierron G; Brennan B; Ferrari A; Chibon F; Bisogno G; De Salvo GL; Chakiba C; Corradini N; Minard-Colin V; Kelsey A; Ranchère-Vince D
Cancer Med; 2018 Apr; 7(4):1384-1393. PubMed ID: 29533008
[TBL] [Abstract][Full Text] [Related]
7. Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors.
Skubitz KM; Geschwind K; Xu WW; Koopmeiners JS; Skubitz AP
J Transl Med; 2016 Feb; 14():51. PubMed ID: 26873324
[TBL] [Abstract][Full Text] [Related]
8. Decreasing iron-related indexes without anaemia in a patient with genetic haemochromatosis.
Conti CB; Baccarin A; Conte D; Fraquelli M
Intern Emerg Med; 2015 Oct; 10(7):839-42. PubMed ID: 26210325
[TBL] [Abstract][Full Text] [Related]
9. PDL1 expression is an independent prognostic factor in localized GIST.
Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
[TBL] [Abstract][Full Text] [Related]
10. [GIST: adjuvant treatment in Austria].
Brodowicz T; Kühr T
Wien Med Wochenschr; 2009; 159(15-16):399-402. PubMed ID: 19696984
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment of GIST: patient selection and treatment strategies.
Joensuu H
Nat Rev Clin Oncol; 2012 Apr; 9(6):351-8. PubMed ID: 22525709
[TBL] [Abstract][Full Text] [Related]
12. Genomic Grade Index predicts postoperative clinical outcome of GIST.
Bertucci F; Finetti P; Ostrowski J; Kim WK; Kim H; Pantaleo MA; Astolfi A; Polkowski M; Birnbaum D
Br J Cancer; 2012 Oct; 107(8):1433-41. PubMed ID: 22929880
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
[TBL] [Abstract][Full Text] [Related]
14. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
[TBL] [Abstract][Full Text] [Related]
15. Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
Rink L; Skorobogatko Y; Kossenkov AV; Belinsky MG; Pajak T; Heinrich MC; Blanke CD; von Mehren M; Ochs MF; Eisenberg B; Godwin AK
Mol Cancer Ther; 2009 Aug; 8(8):2172-82. PubMed ID: 19671739
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
